Eli Lilly announced it will buy Merida Biosciences for up to $2.88 billion in cash to expand its treatments for immune-related and allergic diseases. Merida's lead drug candidate targets autoimmune disorders like Graves' disease and thyroid eye disease, showing promising early results. The acquisition is part of Lilly's strategy to diversify beyond obesity and diabetes drugs. The deal is expected to close in Q4 2026, with Lilly paying an upfront amount plus milestone-based payments.
Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, Lilly's executive vice president and president of Lilly USA and Global Customer Capabilities, will join a firesid...
OpenAI has developed an AI-designed chip called Jalapeno that early tests show outperforms Nvidia's best chip, Blackwell, in total cost of ownership. While Nvidia currently benefits from scarcity in the market, a macro investor predicts this advantag...
Eli Lilly's Phase 3b trials show that combining Taltz (ixekizumab) and Zepbound (tirzepatide) maintains or improves psoriasis and psoriatic arthritis outcomes at 52 weeks compared to Taltz alone in patients with obesity. The combo also sustains benef...
Employer insurance coverage for GLP-1 weight-loss drugs in the U.S. fell from 72% in 2025 to 60% in 2026, signaling cost concerns among employers. Despite this, Eli Lilly's revenue surged 47.7% in Q2 2026, driven by strong sales of Zepbound and Mounj...
